Large Cap Biopharmaceuticals Winners And Losers 2015-16: Which Stocks Can Outperform The ETFs In 2016?… Part 1

The sector is underperforming the market by 16% YTD, sentiment has been burned by concerns about drug pricing and even the spectre of a Fed rate rise, with potentially less available equity funding, has hit all stocks.